Adlyxin, Lyxumia (lixisenatide) is a protein pharmaceutical. Lixisenatide was first approved as Adlyxin on 2013-01-31. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor.
|Indication||type 2 diabetes mellitus|